Dear ,

In the current issue of the OncoWuXi Newsletter, we would like to share with you our EGFR related in vivo models. Other interesting topics covered in this issue include update in PARP related in vivo models and cancer vaccine discovery capabilities.

OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Targeted Oncology
EGFR Targeted In Vivo Models
(1)    Background of EGFR as drug target
  • EGFR biology
  • Summary of EGFR inhibitors

(2)    EGFR related CDX models
  • PC9, NCI-H1650, A549, NCI-H820, H1975, and HCC827 lung cancer CDX models, validated with Erlotinib, Erbitux, AZD9291, Afatinib, Panitumumab, or Icotinib
  • PC9-luc lung cancer intracranial implantation model, validated with Erlotinib and AZD9291

(3)    EGFR related PDX models
  • EGFR TKI or targeted antibody-sensitive PDX models: LU-01-0055, LU-01-0251, LU-01-0539, LU-01-0752, and LU-01-0737 lung cancer PDX models, validated with Erlotinib, Gefitinib, AZD9291, Afatinib, or Erbitux
  • 10 acquired EGFR TKI or targeted antibody-resistant or low sensitive PDX models, validated with Erlotinib, Gefitinib, Osimertinib, AZD9291, Afatinib, or Erbitux
  • Erlotinib-induced resistant LU-01-0055R lung cancer PDX model

(4)    EGFR related genetically engineered NCI-H1975 and PC9 lung cancer CDX models, validated with Osimertinib, Erlotinib, and Gefitinib

(5)    Genetically engineered Ba/F3 cell lines with EGFR mutation
  • Ba/F3-EGFR-exon 19 del/T790M
  • Ba/F3-EGFR-exon 19 del/T790M/C797S
  • Ba/F3-EGFR-L858R/T790M/C797S
  • Ba/F3-EGFR-exon 19 del/C797S
  • Ba/F3-EGFR-exon 20_V769_D770insASV
  • Ba/F3-EGFR-exon 20_V770_D771insSVD
  • Ba/F3-EGFR-exon 20_V773_D774insNPH
  • Validated with Gefitinib, Erlotinib, Dacomitinib, Brigatinib, Afatinib, Poziotinib, or Osimertinib in vitro or in vivo


PARP Targeted In Vivo Models

  • PARP biology
  • Summary of PARP inhibitors
  • Predictive biomarker for PARP inhibitor sensitivity

(2)      PARP related CDX models
  • MDA-MB-436 breast cancer, CAPAN-1 pancreatic cancer, and H526 SCLC CDX models, validated with ABT-888 or Niraparib

(3)      PARP related PDX models
  • 15 PDX or PDC models with BRCA1 mutation, and 25 PDX or PDC models with BRCA2 mutation
  • LU-01-0547 SCLC PDX model, validated with ABT-888 and Olaparib
  • BR-05-0022, BR-05-0028, and BR-05-0014 breast cancer PDX models, validated with Olaparib or Niraparib
  • CO-04-0003 colorectal cancer, LI-03-0014 liver cancer, and PC-07-0003 pancreatic cancer PDX models, validated with Veliparib

(4)      PARP inhibitor induced resistant CDX models
  • Olaparib-induced resistant MDA-MB-436 breast cancer CDX model
  • BMN-673-induced resistant CAPAN-1 pancreatic cancer CDX model
Immuno-Oncology
Cancer Vaccine Discovery Capability
(1)    Background of cancer vaccine
  • History of tumor antigens and cancer vaccines
  • Mechanism of an effective cancer vaccine
  • The typical workflow for cancer vaccine discovery

(2)    Case studies of cancer vaccine discovery
  • Determine immunogenicity of peptides using Elispot assay
  • In vivo validation of predicted peptides in B16F10 or CT26 tumor models
  • In vivo validation of peptide-loaded DC vaccine in B16F10 tumor model

We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

 
Best regards,
WuXi AppTec OncoWuXi Team